Vanguard Investments Australia
PHAT icon

Vanguard Investments Australia’s Phathom Pharmaceuticals PHAT Stock Holding History

Vanguard Investments Australia’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Hold
11,276
– – ﹤0.01% 2278
2026
Q1 		$125K Buy
+11,276
New +$142K ﹤0.01% 2228

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Investments Australia's PHAT Position: Q2 2026 in Review

Vanguard Investments Australia held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 11,276 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #2278.

Vanguard Investments Australia first reported a position in PHAT in Q1 2026 and has held it in 2 quarters since. The position peaked at $125K in Q1 2026. 146 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Vanguard Investments Australia held 11,276 shares of Phathom Pharmaceuticals worth $122K as of Q2 2026.
  • Vanguard Investments Australia left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2278 holding.
  • Vanguard Investments Australia first reported a position in Phathom Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Investments Australia's Phathom Pharmaceuticals position peaked at $125K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.